Loading...
Loading...
- Atara Biotherapeutics Inc ATRA has announced a combined long-term overall survival (OS) analysis from three studies of tabelecleucel (tab-cel) in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ transplantation (SOT).
- Results were presented at the American Transplant Congress.
- Combined objective response rate (ORR) and OS data across two SOT subgroups – relapsed or refractory to rituximab (R/R) monotherapy and R/R to rituximab + chemotherapy (CT) – showed one and 2-year OS for patients achieving either complete response (CR) or those achieving a partial response (PR).
- All patients with a complete response or a partial response to tab-cel were alive at one year.
- Tab-cel was well-tolerated, and no emerging safety concerns and no instances of tumor flare reaction, infusion-related reactions, graft versus host disease, cytokine release syndrome, neurotoxicity, or organ rejection were reported.
- Price Action: ATRA shares are up 5.42% at $13.89 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in